InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.044 0.041 (1,366.67%)+
Announcement
Release
6 Nov 2025 10:47AM
Price at Release
$0.003
Full Release
download
Summary
Chimeric Therapeutics Limited responded to an ASX Query Letter regarding their ADVENT-AML clinical trial results. The trial, which utilized CHM’s CORE-NK technology, indicated promising safety and efficacy outcomes, with no dose-limiting toxicities observed. Notably, CORE-NK cells persisted in patients' blood for more than two weeks post-infusion. The company's response highlighted that 57% of high-risk frontline subjects showed clinical responses, and two additional complete responses were recorded in the Phase 1b of the trial. This new information was disclosed following the initial market announcement, which did not include these updates. The trial is largely supported by the MD Anderson Cancer Center.
Key Points
  • CHM’s ADVENT-AML trial showed no dose-limiting toxicities.
  • Chimeric Therapeutics Technology was used in the trial.
  • CORE-NK cells persisted in patients' blood for over two weeks.
  • Fifty-seven percent of high-risk subjects treated showed clinical responses.
  • Two new complete responses were achieved in the Phase 1b portion of the trial.
  • New information was disclosed after the original announcement.
  • The study was funded by MD Anderson Cancer Center.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.